Cardiff Oncology, Inc. Common Stock vs. Immunovant, Inc. Common Stock
CRDF
Cardiff Oncology, Inc. Common Stock
$0.96 +0.57%
VS IMVTImmunovant, Inc. Common Stock
$39.74 +1.17%
Immunovant, Inc. Common Stock (IMVT) comes out ahead, leading on 2 of 2 compared factors.
Size & Scale
| CRDF | IMVT | |
|---|---|---|
| Market Cap | $74.71 million | $8.21 billion |
| Net Income (TTM) | — | $-505,606,000 |
IMVT leads on 1 of 1 size & scale factors.
Valuation
| CRDF | IMVT | |
|---|---|---|
| Price / Book | — | 9.63 |
CRDF and IMVT split the valuation factors evenly.
Profitability
| CRDF | IMVT | |
|---|---|---|
| Return on Equity | — | -59.30% |
CRDF and IMVT split the profitability factors evenly.
Risk & Sentiment
| CRDF | IMVT | |
|---|---|---|
| Short Interest | 1.17% | 0.15% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: CRDF overview, CRDF financials, IMVT overview, IMVT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.